Related Experiment Video
Updated: Jun 24, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug updates and approvals: 2019 in review
Lauren Hartsell Crump1, Miranda Benfield, Caleb Ramey
1Lauren Hartsell Crump is a PGY-1 pharmacy resident at Novant Health Presbyterian Medical Center, Charlotte, N.C. Miranda Benfield is a PGY-1 pharmacy resident at Carolinas Medical Center, Charlotte, N.C. Caleb Ramey is a PharmD candidate at Wingate University School of Pharmacy, Wingate, N.C. Ashley Arcara is a PharmD candidate at Wingate University School of Pharmacy, Wingate, N.C. Sebin Yang is a PharmD candidate at Wingate University School of Pharmacy, Wingate, N.C. Jenna Brown is a PharmD candidate at Wingate University School of Pharmacy, Wingate, N.C. Geoffrey Mospan is an assistant professor of pharmacy at Wingate University School of Pharmacy, Wingate, N.C. Cortney Mospan is an assistant professor of pharmacy at Wingate University School of Pharmacy, Wingate, N.C.
Abstract:
In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent).
Related Concept Videos
Drug Regulation
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
Therapeutic Drug Monitoring: Overview and Classification
Modified-Release Drug Delivery Systems: Overview

